Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: Subanalysis of patients with renal impairment in the phase iii MMY-3021 study

Haematologica

Volumn 100, Issue 5, 2015, Pages e207-e210

  Moreau, Philippe ^a   Pylypenko, Halyna ^b   Grosicki, Sebastian ^c   Karamanesht, Ievgenii ^d   Leleu, Xavier ^e   Rekhtman, Grigoriy ^f   Masliak, Zvenyslava ^g   Robak, Pawel ^h   Esseltine, Dixie Lee ⁱ   Feng, Huaibao ^j   Deraedt, William ^k   Van De Velde, Helgi ^k   Arnulf, Bertrand ^l  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b Cherkassy Regional Oncology Dispensary ^*  (Ukraine)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

^d Kiev BMT Centre   (Ukraine)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f Khmelnitskiy District Hospital   (Ukraine)

^g Hematology Department of the Academy of Medical Sciences of Ukraine   (Ukraine)

^h MEDICAL UNIVERSITY OF LODZ   (Poland)

ⁱ MILLENNIUM PHARMACEUTICALS INC   (United States)

^j JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^k JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^l SAINT LOUIS HOSPITAL   (France)

more..

Author keywords

Intravenous bortezomib; MM patients; Relapsed multiple myeloma; Renally impaired

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BODY WEIGHT DISORDER; CANCER RECURRENCE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE CLEARANCE; DIARRHEA; DOSAGE SCHEDULE COMPARISON; FATIGUE; FEMALE; FEVER; HEART INFARCTION; HUMAN; KIDNEY FAILURE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NAUSEA; NEURALGIA; NEUROPATHIC PAIN; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; SUDDEN DEATH; THROMBOCYTOPENIA; VIRAL CONJUNCTIVITIS; VOMITING; WEIGHT REDUCTION; COMPLICATION; CUTANEOUS DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; PATHOLOGY; RENAL INSUFFICIENCY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INTRAVENOUS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; BORTEZOMIB; HUMANS; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PYRAZINES; RENAL INSUFFICIENCY; TREATMENT OUTCOME;

EID: 84925952101     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.118182     Document Type: Article

References (15)

1. Chanan-Khan AA, San Miguel JF, Jagannath S, Ludwig H, Dimopoulos MA. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment. Clin Cancer Res. 2012;18(8):2145-2163.
2. Dimopoulos MA, Delimpasi S, Katodritou E, et al. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol. 2014;25(1):195-200.
3. Bringhen S, Mateos MV, Zweegman S, et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica. 2013;98(6):980-987.
4. Eleutherakis-Papaiakovou V, Bamias A, Gika D, et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma. 2007;48(2):337-341.
5. Blade J, Sonneveld P, San Miguel JF, et al. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. Clin Lymphoma Myeloma. 2008;8(6):352-355.
6. Dimopoulos MA, Richardson PG, Schlag R, et al. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol. 2009;27(36):6086-6093.
7. San-Miguel JF, Richardson PG, Sonneveld P, et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia. 2008;22(4):842-849.
8. Scheid C, Sonneveld P, Schmidt-Wolf IG, et al. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMGHD4 trial. Haematologica. 2014;99(1):148-154.
9. Dimopoulos MA, Roussou M, Gavriatopoulou M, et al. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. Clin Lymphoma Myeloma. 2009;9(4):302-306.
10. Chanan-Khan AA, Kaufman JL, Mehta J, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood. 2007;109(6):2604-2606.
11. Ludwig H, Adam Z, Hajek R, et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol. 2010;28(30):4635-4641.
12. Roussou M, Kastritis E, Christoulas D, et al. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res. 2010;34(10):1395-1397.
13. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431-440.
14. Arnulf B, Pylypenko H, Grosicki S, et al. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica. 2012;97(12):1925-1928.
15. Lok A, Mocquard J, Bourcier J, et al. Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma. Haematologica. 2014; 99(3):e33-e34.